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SUMMARY
The debate around value in oncology drug selection has been prominent in 
recent years, and several professional bodies have furthered this debate 
by advocating for so-called value frameworks. Herein, we provide a view-
point on these value frameworks, emphasizing the need to consider 4 key 
aspects: (1) the economic underpinnings of value; (2) the importance of 
the perspective adopted in the valuation; (3) the importance of the dif-
ference between absolute and relative measures of risk and measuring 
patient preferences; and (4) the recognition of multiple quality-of-life (QoL) 
domains, and the aggregation and valuation of those domains, through 
utilities within a multicriteria decision analysis, may allow prioritization of 
QoL above the tallying of safety events, particularly in a value framework 
focusing on the individual patient.
While several frameworks exist, they incorporate different attributes 
and—importantly—assess value from alternative perspectives, including 
those of patients, regulators, payers, and society. The various perspectives 
necessarily lead to potentially different, if not sometimes divergent, conclu-
sions about the valuation. We show that the perspective of the valuation 
affects the framing of the risk/benefit question and the methodology to 
measure the individual patient choice, or preference, as opposed to the  
collective, or population, choice. 
We focus specifically on the American Society of Clinical Oncology 
(ASCO) Value Framework. We argue that its laudable intent to assist in 
shared clinician-patient decision making can be augmented by more for-
mally adopting methodology underpinned by micro- and health economic 
concepts, as well as application of formal quantitative approaches. Our rec-
ommendations for value frameworks focusing on the individual patient, such 
as the ASCO Value Framework, are 3-fold: (1) ensure that stakeholders  
understand the importance of the adopted (economic) perspective; (2) 
consider using exclusively absolute measures of risk and formal patient-
preference methodology; and (3) consider foregoing safety parameters for 
higher-order utility considerations.
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VIEWPOINTS
The debate around value in health care, and specifically in oncology drug selection, has been highly prominent in recent years.1-5 A number of professional bodies 
(including the Memorial Sloan Kettering Cancer Center, the 
American Society of Clinical Oncology [ASCO], the National 
Comprehensive Cancer Network, the Institute for Clinical 
and Economic Review, and the European Society of Medical 
Oncology [ESMO]) have furthered this debate by introducing 
so-called value frameworks.1,2,6-10 Each value framework cap-
tures similar, as well as different, aspects of clinical and eco-
nomic value and cost. These value frameworks have been well 
described1,2,6,7,11,12 and critiqued2,10,13-33 to highlight potential 
areas for improvement. In this article, we focus on the ASCO 
Value Framework, since it is based in the United States and 
specifically intended to address the interaction between health 
care provider (HCP) and individual patient. We address the fol-
lowing 4 aspects by applying microeconomic concepts, while 
recognizing that behavioral economics may provide additional 
thinking34: (1) reintroduce the debate around the concept of 
value in more formalized microeconomic terms; (2) clarify the 
importance of the economic perspective adopted in the valu-
ation; (3) critically appraise the use of certain statistical mea-
sures in the context of the patient-HCP interaction, specifically 
the difference between relative and absolute measures of risk, 
as well as using formal patient-preference methodology; and 
(4) provide rationale supporting the foregoing of safety param-
eters for higher-order utilities.
■■  Definitions of Value
The term “value” in health care is used abundantly, yet a single 
definition does not appear to exist nor is likely to emerge. 
The main reason for this lack of definition can be found in a 
phrase from economist Joan Robinson about the related con-
cept of utility. She writes: “Utility is a metaphysical concept of 
impregnable circularity; utility is the quality in commodities 
that makes individuals want to buy them, and the fact that 
individuals want to buy commodities shows that they have 
utility.”35 Ultimately, the value of a commodity depends on 
one’s willingness to trade for something else that has value. 
This may be the remote risk of a serious side effect for the pos-
sibility of additional years of life or anything else that has value. 
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by certain non-U.S. national payer agencies that use Equation 2 
for reimbursement decisions, as well as the Institute for 
Clinical and Economic Review in the United States.
Equation 2 expresses the ratio of inputs and outputs at the 
margin through a marginal or incremental analysis, calculat-
ing the difference in cost and outcome of the intervention, 
compared with its next best alternative. Marginal analysis 
is a fundamental tenet of health economics and provides an 
absolute (i.e., difference) measure of value.39 This difference 
between relative and absolute measures of risk is a key point 
in expressing value and is closely related to the perspective we 
take in answering the question “Value to whom?” In addition, 
using the ratio in a marginal analysis explicitly introduces the 
trading, and, hence, “valuing” of additional life (outcome) for 
additional money (cost).
■■  Perspective of the Valuation
When answering the question “Value to whom?” one quickly 
gets into formal issues of economic perspective. Many people 
would argue that this should be the individual patient’s per-
spective; however, there are many different types of patients, as 
well as collective groups of stakeholders with varying objectives, 
standing up for different parts of society. For example, special-
ist societies on behalf of their patient base or budget-holders on 
behalf of all patients to be treated within their budgets.
In Table 1, we summarize the various perspectives of key 
stakeholders that are either explicitly mentioned or implicitly 
addressed in the various value frameworks and include the 
types of questions that these different stakeholders may ask. 
Table 1 illustrates the need to be precise about how the attri-
butes addressing these questions would have to be communi-
cated. It becomes apparent that, while some of the questions 
that different stakeholders might ask require the same mea-
sures of benefit (i.e., risk reduction), many questions invoke the 
need for different concepts.
In the next section of this article, we focus on the individual 
patient’s perspective, as opposed to the population viewpoint 
that regulators and payers need to take. Table 1 highlights that, 
unlike other stakeholders, individual patients as consumers of 
health care are more likely to ask questions in terms of chance 
and generally ask questions in absolute terms, such as: “How 
long (requires an absolute measure) may I expect (invokes 
probability) to live with this condition?” This type of question-
ing has important implications for the measures of benefit that 
can be used to answer such questions, while also considering 
probability-based answers.
To illustrate the individual patient perspective further, we 
outline potential relevant risk reduction measures and para-
phrase the ways these measures would have to be articulated 
in an HCP-patient interaction. Table 1 attempts to explain the 
Thus, when following this idea, one might question whether 
it is correct to define value, as suggested by Porter (2010), to 
contain a numerator and a denominator, with outcome being 
the numerator and costs being the denominator36:
1. Value = Outcome ÷ Cost
Nevertheless, in the U.S. third-party payer context, Equation 1 
may be viewed as a generally accepted way of expressing 
value. Equation 1 may also be viewed as a cost-consequence 
analysis,37 in which outcomes and costs are tallied, yet not 
aggregated, into a single measure. Equation 1 expresses the 
ratio of an intervention’s outputs for its cost; for example, the 
intervention produces, on average, 21 months of survival for 
a given cost of, say, $100,000. Therefore, the value according 
to Equation 1 is 1.75 (life-years) ÷ $100,000, or expressed in 
words: “Providing 1.75 years of life for a cost of $100,000.” 
For the advanced disease setting, the outcome measures in 
the updated version of the ASCO Value Framework31 include the 
hazard ratio (HR) for overall survival (OS) or progression-free 
survival (PFS), median OS or PFS or response rate (RR), toxicity, 
an assessment of the tail of the survival curve, palliation, QoL, 
and the absence or presence of a treatment-free interval. For 
the adjuvant setting, the outcome measures include the HR for 
OS or disease-free survival (DFS), median OS or DFS, toxicity, 
and the tail of the curve. The ASCO Value Framework may be 
viewed as a cost-consequence analysis in which an actual score 
for the consequences is tallied up and juxtaposed against the 
wholesale acquisition cost and/or the patient copay.38 Hence, 
the ASCO framework is a major step forward from Equation 1, 
since it aims to quantify good value. 
Another measure, introduced over 40 years ago and used 
in formal economic evaluation, or cost-effectiveness analysis 
(CEA) of health care interventions, is called the incremental 
cost-effectiveness ratio (ICER).39 This measure is a key crite-
rion of the value framework of the Institute for Clinical and 
Economic Review.6 
2. Incremental Cost-Effectiveness Ratio = Cost(A)–Cost(B)
 Outcome(A)–Outcome(B)
Cost encompasses all direct medical costs and outcomes 
in a CEA. In oncology, the outcome measure is usually OS or 
quality-adjusted survival, when available, resulting in a cost-
utility analysis. In the latter, the denominator is the difference 
in quality-adjusted life-years (QALYs).39 Equation 2 may be 
characterized by a numerator of, for example, 21-15 months of 
incremental survival, assuming that the comparator agent pro-
vides 15 months of survival, and a cost difference of $100,000-
$50,000, assuming that the comparator cost is $50,000; hence, 
the ICER is $50,000 per 0.5 life-years gained, or $100,000 
per life-year gained. Moreover, thresholds in terms of cost per 
QALY for what may be considered good value for money are set 
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measure of benefit in readily understood terms, while holding 
true, as much as possible, to their formal statistical definitions. 
Finally, oncology can also take a page from extensive risk pre-
diction work in the cardiovascular space, with equations such 
as the Framingham risk equations, where simple online risk 
calculators allow one to estimate a patient’s absolute 10-year risk 
of death based on a set of validated risk factors or covariates.40
■■  Measures of Risk and Their Relevance  
to the Individual Patient
In Table 2, we use definitions of various measures of rela-
tive and absolute risk as they would need to be explained 
to a patient in an HCP-patient interaction. Table 2 helps 
clarify why absolute measures of risk are generally better 
ways to assist a patient, as a health care consumer, in shared 
TABLE 1 Perspectives of Stakeholders Relevant to Value Frameworks in Immuno-Oncology
Stakeholder Perspective Wants to Understand
Relevant Measures and Concepts of Benefit (Risk 
Reduction)
Patient Consumer of 
health care 
intervention
What happens if I take the drug? What happens if I don’t? Invokes probability and independent predictors of survival  
(if known)
What are my chances of the drug working? Invokes probability and risk factors
How (much) long(er) will I live? Invokes probability, mean survival, median survival, and the 
shape of the survival curve
What is my chance of living another year?
What is my chance to be a “long-term” survivor?
Invokes the shape of the survival curve and potentially  
certain trade-off decisions
Will I be able to function and do the things I used to?
Will I be able to continue on “as normal,” or not?
Invokes quality measures of survival and their measurement 
and uncertainty
Is this drug safe for me to take?51 Invokes probability and absolute rates (%) of AEs, SAEs, NNH
How much will this cost? Invokes cost measures, such as copay amounts, deductibles, 
and potentially lifetime caps
Health care 
provider
Provider of 
health care 
intervention
Do I have a reasonable expectation that the intervention will 
work in my patient?
May be a mix of relative and absolute measures of effect. 
Invokes probabilities and (if data exists) potential (patient-
individualized) risk-stratification
How can I minimize/avoid causing harm? Absolute rates (%) of AEs, SAEs and an assessment of the 
“risk/benefit” profile
How can I improve the overall well-being of the patient? Invokes QoL considerations and psychosocial domains
Regulator Assessor of 
“risk/benefit 
ratio” (safety 
and efficacy)
Is the clinical effect proven and do the efficacy outcomes outweigh the adverse effect profile? Specifically:
(a) Did the study meet its primary endpoint, secondary  
endpoints (if a hierarchical test was employed)?
Key measure of effect is the HR
Additional measure is (incremental) median survival
Other measures can relate to (statistics of) secondary 
endpoint(s)
(b) Do we believe the drug’s adverse effect profile to be 
acceptable, given the remaining level of medical unmet 
need in this disease state?
Absolute rates (%) of AEs, SAEs and an assessment of the 
“risk/benefit” profile
Payer Health care 
system
Similar questions as the regulator AND
Does the trial population address the population I am  
covering?
Requires RWD and potentially additional modeling 
approaches
How many patients need treatment to avoid 1 event? Invokes ARR and NNT (1/ARR)
Is the comparator drug relevant? Relates to the standard of care and “next best alternative” for 
marginal analysis in health economics
What cost offsets did the drug show, if any? Requires a cost-consequence analysis
What is the price?
What is the anticipated volume of patients and what is the 
impact on my budget?
Requires financial modeling
Does it provide value-for-money? Requires Equation 1 or 2
Is it cost-effective? Requires Equation 2
Society Society as a 
whole
Is there ancillary value to society outside of “direct medical 
costs,” by way of “indirect costs,” such as reduced absenteeism,  
presenteeism, and avoiding loss of work productivity?
Requires indirect costing methodology, time and motion  
studies, and patient-preference methodology
Note: Mean survival can be readily shown to be equivalent to the area under the survival curve; hence, incremental mean survival can be shown to be equivalent to  
additional months/years of life gained.52
AE = adverse event; ARR = absolute risk reduction; HR = hazard ratio; NNH = number needed to harm; NNT = number needed to treat; QoL = quality of life;  
RWD = real-world data; SAE = serious adverse event.
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decision making, compared with relative measures, since they 
more directly provide answers to questions of most interest to 
patients.41 It is also noted that the standard, relative measures 
of risk used in regulatory evaluations, in particular, fall short 
in addressing the types of questions that patients likely have 
regarding a therapeutic immuno-oncologic intervention. The 
regulatory perspective is included in Table 1 to underscore 
the context for relative measures of risk required for regula-
tory evaluation, which often shape the HCP perspective and 
vernacular of communicating risk, as reflected by the ASCO 
Value Framework. In addition, Table 2 clarifies that probability 
and preference-based concepts can further facilitate capture of 
the individual patient perspective.42
The exercise of articulating the measures used in the 
value frameworks, with the patient as the audience, clarifies 
the following: Relative measures of risk reduction, such as 
relative risks, odds ratios, and hazard ratios (HR), are dif-
ficult to articulate correctly and intuitively to a layperson. In 
Stakeholder/Perspective Wants to Understand
What Measure of Risk 
Reduction Can Address  
the Question?
Measure in Value 
Framework?a
How Might the Answer be Articulated 
Within the HCP-Patient Interaction
Patient/consumer of  
health care intervention
How (much) long(er) 
will I live?
Using incremental  
median survival
ASCO, ESMO “Fifty percent of the population studied 
in the trial of this drug survived for 16 
months. This was 4 months longer than 
for the drug with which it was compared.”
Using the HR ASCO, ESMO Strict definition: The treatment in question 
will cause the patient to reach death more 
slowly (delay death) compared with the 
alternative; a treated patient that has not 
yet died by a certain time has a chance of 
dying at the next (measured) time point, 
defined by the HR (i.e., if HR = 0.5 then 
chance = 50%).
Loose definitionb: The reduction in risk rel-
ative to the agent this drug was compared 
with was 50% (if HR = 0.50; 1-HR = 50%).
Using incremental mean 
survival = life-years gained
MSKCC “The average patient in the trial survived 
for 19 months. This was 4 months lon-
ger than for the drug with which it was 
compared.”
What is my individual 
chance of being one of 
those long-term  
survivors?
Using probability of  
survival
Not captured explicitly 
in any framework. ASCO 
mentions “landmark” (%) 
survival at survival times 
relevant to the tail of an 
immuno-oncology survival 
curve
“There appear to be about 20% of patients 
that survive beyond 3 years.”c
Using the shape of an 
immuno-oncology survival 
curve (as opposed to that 
of chemotherapy)d
ASCO updated framework 
has bonus points for the 
tail; none include patient 
preference
“Using this immuno-oncology agent, 
there are/appear to be some patients who 
survive (more) long-term…the science to 
predict your individual chance needs to 
evolve to be able to answer your question 
for you specifically.”c,d
Will I be able to con-
tinue on “as normal,” 
or not?
A measure that can be 
used is the Trial Outcome 
Index, which assesses QoL 
and functional well-being
QoL is acknowledged in 
ASCO, ESMO, and ICER 
value frameworks
“There were some meaningful improve-
ments observed in QoL and functional 
well-being of the patients that were 
studied.”
aThe NCCN Evidence Blocks are not mentioned in this table, since they do not at this time explicitly provide clarification of which measures to use to estimate value, unlike 
the ASCO, ESMO, MSKCC, and ICER frameworks.
bThis definition is often reported in the medical literature.41
cFor simplicity, we assume that there are no known risk factors for the condition or indications to predict long-term survivors.
dThe concept of a survival curve tail in an immuno-oncology curve has gained more widespread acceptance.53 The explanation for this phenomenon and the underlying 
analytical models for such survival curves, however, are in their infancy, with explanations ranging from treatment heterogeneity, to time-dependent hazards, to cohorts 
that behave differently.54,55 The immuno-oncology survival curves also appear to demonstrate lower incremental medians, as would be predicted from the simple propor-
tional hazards assumption.
ASCO = American Society of Clinical Oncology; ESMO = European Society for Medical Oncology; HCP = health care provider; HR = hazard ratio; ICER = Institute for 
Clinical and Economic Review; MSKCC = Memorial Sloan Kettering Cancer Center; NCCN = National Comprehensive Cancer Network; QoL = quality of life.
TABLE 2 Select Measures of Risk and Their Articulation in a Putative HCP-Patient Interaction, from Table 1
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addition, literature supports the use of absolute measures of 
risk in oncology patient communication, since unlike relative 
risks, they do not tend to overestimate the magnitude of the 
benefit as perceived by the patient.41,43-45 
In addition, such measures, while particularly valuable from 
a regulator’s perspective, are much less so from an individual 
patient perspective. Absolute measures of risk reduction, such 
as additional months of survival, are more intuitive to the 
patient and therefore can be considered more “patient-relevant.” 
The revision of the ASCO Value Framework also acknowledges 
some of these issues: “To avoid the misinterpretation that a 
favorable HR necessarily represents a large absolute gain in OS 
or PFS, it is incumbent upon the physician, at the point of care, 
to explain the absolute difference in survival (e.g., on average, a 
patient can expect an improvement of x weeks or months) with 
the test regimen when compared with the standard of care. It 
is essential to understand that the framework is meant to be 
modified at the point of care, as a physician and patient final-
ize a regimen.”31 The ESMO Value Framework has recognized 
this also and reports on the relationship between the HR and 
incremental months of OS, scrutinizing for face validity, coher-
ence, and consistency.7
It is important to note that with an individual patient in 
mind, the individual’s likelihood of an event also needs to 
be considered. Even a concept such as mean, or average, sur-
vival,31 while arguably more accurate from a patient’s stand-
point than median survival, does not account for the individual 
patient perspective. Note that use of the word “average” in the 
ASCO Value Framework is incorrect. “Average” equates to the 
restricted mean survival, which is mathematically equivalent 
to the area under the curve in the absence of censoring. Mean 
survival is by definition greater than median survival for sur-
vival-time distributions, which are typically right-skewed; this 
point is particularly relevant for immuno-oncology survival 
curves demonstrating the now well-known tail (i.e., displaying 
nonproportional hazards behavior).46-48 
However, mean survival also does not allow for the patient’s 
preference to be accounted for in a meaningful way. For 
instance, it has been shown that a majority of cancer patients 
prefer a “hopeful gamble” (i.e., providing a lower possibility 
of longer-term survival, such as might be afforded by the tail 
of an immuno-oncologic) over a “safe bet” offering a certain 
median survival and thus may be willing to accept a risk of 
greater short-term mortality in exchange for a lower chance 
at a large, more meaningful gain in survival.47 The updated 
ASCO Value Framework does recognize the value of the tail in 
immuno-oncology and has incorporated this into its updated 
framework,31 but it does not yet go as far as considering patient 
preference related to the possibility of being part of that tail.
■■  Multicriteria Decision Analysis, QoL, and Utility
One might argue that all value frameworks may be viewed 
as simple, practical forms of multicriteria (attribute) decision 
(utility) analysis. Utility is a way of valuing QoL and repre-
sents an individual’s relative satisfaction with a health state, 
on a scale from 0 (representing death) to 1 (representing per-
fect health).42 The European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire Core 30 
(EORTC QLQ-C30) is an instrument frequently used to mea-
sure quality of life in cancer patients.48 The EQ-5D is a well-
described utility instrument aimed at valuing general health 
through domains of mobility, self-care, usual activities, pain/
discomfort and anxiety/depression.16,49 Efforts to map the rela-
tionship between the EORTC QLQ-C30 and EQ-5D-based util-
ity values at the individual patient level have been performed.48 
This field continues to evolve and is worth tracking closely to 
gain further insight into how individual patients value various 
QoL domains. 
These QoL considerations may supersede individual side 
effects, since their implications tend to “ladder up” to more 
overarching QoL considerations. This therefore raises the ques-
tion of whether in a value framework intended for the individ-
ual patient, the safety of a compound can be left out altogether 
as long as an acceptable form of capture of patient-relevant QoL 
is included and valued in a utility score.50 
■■  Discussion
The concept of value in oncology has gained tremendous trac-
tion over the last few years. While there exist various definitions 
of value, some qualitative (e.g., Equation 1) and some quantita-
tive (e.g., Equation 2), perhaps the most important aspect in 
this debate is to be thoughtful about what definition of value 
may be most appropriate, given the perspective of the audience 
(see Table 1). We have focused on the ASCO Value Framework 
and its laudable intent to attempt to clarify elements of value 
that can be communicated within the HCP-patient interac-
tion. We performed a mental exercise of articulating various 
measures of risk and critically appraised their relevance from 
the individual patient’s perspective. We argue that by adopting 
the individual patient perspective, the components for further 
improvement of the existing value frameworks, notably by 
ASCO, become more self-evident. 
■■  Recommendations
Our recommendations are that a value framework focused 
on the individual HCP-patient interaction can benefit from 
3 straightforward, yet important further improvements: (1) use 
exclusively absolute measures of risk; (2) augment the frame-
work through recognizing that valuation of outcomes by the 
individual patient has a probabilistic element to it and apply 
established patient-preference methodology to capture value 
trade-offs (e.g., per the previously mentioned hopeful gambles 
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